Development of EPS221 and EPS222 for psychiatric and cardiovascular diseases. Co-develop 505(b)2 new drugs with Pharmaceutical Partners, Swiss Pharmaceutical Co., Ltd. and Pharmadax Inc., to expand R&D program.
News
We will use cookies and other information to optimize your experience. By continuing to browse, you consent to our use. For details, please read Privacy Policy
